CLEANWATTS
11.8.2022 12:43:09 CEST | Business Wire | Press release
Cleanwatts, the leading climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world, presents Soma Demeny as VP of HR, assuming the responsibility of leading our most important assets: people .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220811005340/en/
Soma Demeny began his career in Deutsche Telekom, subsequently spending 17 years with General Electric (GE) where he led human resource teams in Finance, Digital and Corporate divisions. Soma’s international career is centered on helping service and manufacturing organizations scale, grow and adapt to change through the implementation of world-class human resource infrastructures and best practices. More recently, Soma directed much of his time and expertise to help smaller mid-market companies reorganize and adapt to change.
Soma carries degrees in Business Studies and Human Resources Management and is a graduate of GE’s prestigious Human Resources Leadership Program. Soma is Hungarian and has lived in the UK, Austria, and South America. Among Soma’s defining characteristics are curiosity, agility, creativity and fun. As a father of two and a company cultural ambassador, this remains a key philosophy for Soma.
When asked why he joined Cleanwatts, Soma replied pointedly: “Who wouldn’t want to be part of changing the world?”
Cleanwatts’ appointment of Soma Demeny is yet another important decision taken by the company in recent months. It reflects Cleanwatts’ commitment to building a healthy, vibrant and talented organization able to travel at market speed. Michael Pinto, Cleanwatts co-founder and CEO, describes Soma as “a world-class HR Leader, out-of-the-box thinker and a person that connects very easily with people through his critical thinking, emotional intelligence, and clear communication style.”
Soma will be responsible for designing and overseeing the company’s HR strategy, including recruitment and employee retention programs, evaluating and improving the company’s employee value proposition, training and development plans, as well as creating a safe workplace, healthy and inspirational culture as the organization continues to build a world in which clean energy is decentralized, digitalized, and democratized.
Ends
About Cleanwatts
We are a climate tech company committed to simplifying, amplifying, and accelerating the energy transition for communities around the world. We achieve this by optimizing the consumption, generation, storage, trading, and balancing of clean energy, where it matters most: locally.
We deliver value by creating and managing Renewable Energy Communities, deploying our domain expertise, proprietary technology, financial capital, and management capabilities for the benefit of our clients.
At the heart of our offering stands Cleanwatts™ OS, our Operating System specifically designed to manage energy communities. Cleanwatts™ OS is a modular, interoperable, and localizable cloud-based platform that seamlessly connects the dots between behind-the-meter optimization for community members, front-of-the-meter grid resiliency, and transaction management for local energy markets.
We are now actively managing a growing list of over 100 energy communities built by our very own REC Factory: a highly skilled cross-functional team, committed to working closely with anchor clients, town halls, and other community members to develop the best solution for each local community that we serve. Building on the success of our first REC Factory in Portugal, we’re now replicating this level of engagement in other geographies around the world.
We are building a world in which clean energy is decentralized, digitalized, and democratized.
Follow Cleanwatts on LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005340/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
